
|Articles|November 15, 2003
Allergan to buy Oculex for $230 million in cash
New York-Allergan Inc. will pay nearly $230 million in cash to acquire Oculex Pharmaceuticals Inc., a privately held company specializing in the development of treatments for sight-threatening diseases of the eye.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
US FDA awards Epion Therapeutics EpiSmart cross-linking system Fast Track designation
2
Abeona Therapeutics’ ABO-503 chosen for FDA's Rare Disease Endpoint Advancement Pilot Program
3
Treating myopia today: US-focused treatments, challenges, and global insights
4
FDA clears BVI’s FineVision HP trifocal IOL for the US market
5